Business
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
BASKING RIDGE, N.J. & RAHWAY, N.J., August 18, 2025--Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":10600,"height":1888,"url":"https://media.zenfs.com/en/business-wire.com/2c06e0eec314dc56fa92b74944cf05e3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wrtmDmcV9OMyuUOxYY_qag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2c06e0eec314dc56fa92b74944cf05e3","width":960,"height":171},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.aWV32MXpbxYiXkfhNgw_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00Mjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/2c06e0eec314dc56fa92b74944cf05e3","width":1200,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Data from IDeate-Lung01 trial will be presented at upcoming IASLC 2025 World Conference on Lung Cancer","length":102,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"First Breakthrough Therapy Designation for Daiichi Sankyo and Merck’s ifinatamab deruxtecan based on IDeate-Lung01 phase 2 trial, with support from IDeate-PanTumor01 phase 1/2 trial","length":181,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Fourteenth Breakthrough Therapy Designation granted by FDA across the oncology portfolio of Daiichi Sankyo","length":106,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":389,"olType":false},{"type":"text","content":"BASKING RIDGE, N.J. & RAHWAY, N.J., August 18, 2025--(BUSINESS WIRE)--Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.","length":352,"tagName":"p"},{"type":"text","content":"Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and Canada.","length":289,"tagName":"p"},{"type":"text","content":"The FDA BTD is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and ad...